Basit öğe kaydını göster

dc.contributor.authorŞahin, Fahri
dc.contributor.authorSaydam, Güray
dc.contributor.authorCömert, Melda
dc.contributor.authorUz, Burak
dc.contributor.authorYavuz, Akif Selim
dc.contributor.authorTuran, Esra
dc.contributor.authorYönal, İpek
dc.contributor.authorAtay, Hilmi
dc.contributor.authorKeltikli, Engin
dc.contributor.authorTurgut, Mehmet
dc.contributor.authorPehlivan, Mustafa
dc.contributor.authorAkay, Meltem Olga
dc.contributor.authorGürkan, Emel
dc.contributor.authorPaydaş, Semra
dc.contributor.authorKahraman, Selda
dc.contributor.authorDemirkan, Fatih
dc.contributor.authorKırkızlar, Onur
dc.contributor.authorAkpınar, Seval
dc.contributor.authorPamuk, Gülsüm Emel
dc.contributor.authorDemir, Muzaffer
dc.contributor.authorÖzbaş, Hasan Mücahit
dc.contributor.authorSönmez, Mehmet
dc.contributor.authorGültürk, Mine
dc.contributor.authorSalihoğlu, Ayşe
dc.contributor.authorEşkazan, Ahmet Emre
dc.contributor.authorAr, Cem
dc.contributor.authorHaydaroğlu Şahin, Handan
dc.contributor.authorÖngören, Şeniz
dc.contributor.authorBaşlar, Zafer
dc.contributor.authorAydın, Yıldız
dc.contributor.authorYenere, Mustafa Nuri
dc.contributor.authorTüzüner, Nükhet
dc.contributor.authorFerhanoğlu, Burhan
dc.contributor.authorHaznedaroglu, İbrahim C.
dc.contributor.authorİlhan, Osman
dc.contributor.authorSoysal, Teoman
dc.date.accessioned2019-12-10T11:21:04Z
dc.date.available2019-12-10T11:21:04Z
dc.date.issued2013
dc.identifier.issn1300-7777
dc.identifier.urihttps://doi.org/10.4274/tjh.2013.0151
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874976/
dc.identifier.urihttp://hdl.handle.net/11655/15429
dc.description.abstractObjective: here have been tremendous changes in treatment and follow-up of patients with chronic myeloid leukemia (CML) in the last decade. Especially, regular publication and updating of NCCN and ELN guidelines have provided enermous rationale and base for close monitorization of patients with CML. But, it is stil needed to have registry results retrospectively to evaluate daily CML practices. , Materials and Methods: In this article, we have evaluated 1133 patients’ results with CML in terms of demographical features, disease status, response, resistance and use of second-generation TKIs. , Results: The response rate has been found relatively high in comparison with previously published articles, and we detected that there was a lack of appropriate and adequate molecular response assessment. , Conclusion: We concluded that we need to improve registry systems and increase the availability of molecular response assessment to provide high-quality patient care., Conflict of interest:None declared.
dc.relation.isversionof10.4274/tjh.2013.0151
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleTurkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis Of Cml Patients
dc.title.alternativeTürk Kronik Myeloid Lösemi Çalışması: KML Hastalarının Geriye Dönük Kesitsel İncelenmesi
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalTurkish Journal of Hematology
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume30
dc.identifier.issue4
dc.identifier.startpage351
dc.identifier.endpage358
dc.description.indexPubMed
dc.description.indexWoS


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster